Ameriprise Financial Inc. Has $1.46 Billion Stock Holdings in Bristol Myers Squibb Company $BMY

Ameriprise Financial Inc. trimmed its holdings in Bristol Myers Squibb Company (NYSE:BMY) by 0.3% in the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 32,473,834 shares of the biopharmaceutical company’s stock after selling 105,784 shares during the period. Ameriprise Financial Inc. owned 1.60% of Bristol Myers Squibb worth $1,464,552,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also modified their holdings of BMY. Schonfeld Strategic Advisors LLC lifted its position in shares of Bristol Myers Squibb by 4,463.1% in the third quarter. Schonfeld Strategic Advisors LLC now owns 1,178,101 shares of the biopharmaceutical company’s stock worth $52,894,000 after buying an additional 1,152,283 shares during the last quarter. Creative Planning increased its holdings in shares of Bristol Myers Squibb by 16.2% during the 3rd quarter. Creative Planning now owns 523,120 shares of the biopharmaceutical company’s stock valued at $23,593,000 after acquiring an additional 72,927 shares during the last quarter. Lazard Asset Management LLC raised its stake in shares of Bristol Myers Squibb by 5.8% in the 3rd quarter. Lazard Asset Management LLC now owns 396,870 shares of the biopharmaceutical company’s stock valued at $17,899,000 after acquiring an additional 21,733 shares in the last quarter. New England Asset Management Inc. lifted its holdings in Bristol Myers Squibb by 0.8% in the 3rd quarter. New England Asset Management Inc. now owns 40,036 shares of the biopharmaceutical company’s stock worth $1,806,000 after purchasing an additional 315 shares during the last quarter. Finally, Ritter Alpha LP bought a new stake in Bristol Myers Squibb during the third quarter worth approximately $229,000. Institutional investors own 76.41% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently commented on the stock. Piper Sandler reissued an “overweight” rating and issued a $75.00 price target (up from $66.00) on shares of Bristol Myers Squibb in a research report on Monday, February 23rd. HSBC reaffirmed a “hold” rating and set a $53.00 price objective on shares of Bristol Myers Squibb in a report on Wednesday, December 10th. Royal Bank Of Canada began coverage on shares of Bristol Myers Squibb in a report on Tuesday, February 24th. They issued a “sector perform” rating and a $60.00 target price on the stock. The Goldman Sachs Group reissued a “neutral” rating and set a $57.00 target price (up from $51.00) on shares of Bristol Myers Squibb in a research report on Tuesday, December 2nd. Finally, Leerink Partners raised their price target on Bristol Myers Squibb from $54.00 to $60.00 and gave the company an “outperform” rating in a research report on Tuesday, January 13th. Nine equities research analysts have rated the stock with a Buy rating, twelve have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Bristol Myers Squibb currently has a consensus rating of “Hold” and a consensus target price of $61.00.

Bristol Myers Squibb Price Performance

Shares of Bristol Myers Squibb stock opened at $59.02 on Friday. The company has a debt-to-equity ratio of 2.32, a current ratio of 1.26 and a quick ratio of 1.14. The company has a market cap of $120.18 billion, a PE ratio of 17.11, a price-to-earnings-growth ratio of 0.17 and a beta of 0.26. The firm has a fifty day moving average price of $58.24 and a two-hundred day moving average price of $51.43. Bristol Myers Squibb Company has a fifty-two week low of $42.52 and a fifty-two week high of $62.89.

Bristol Myers Squibb (NYSE:BMY) last posted its quarterly earnings data on Thursday, February 5th. The biopharmaceutical company reported $1.26 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.65 by ($0.39). Bristol Myers Squibb had a return on equity of 69.65% and a net margin of 14.64%.The company had revenue of $12.50 billion for the quarter, compared to the consensus estimate of $12.24 billion. During the same quarter in the previous year, the firm posted $1.67 EPS. The business’s revenue for the quarter was up 1.3% compared to the same quarter last year. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. Analysts expect that Bristol Myers Squibb Company will post 6.74 EPS for the current year.

Bristol Myers Squibb Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, May 1st. Shareholders of record on Thursday, April 2nd will be issued a $0.63 dividend. The ex-dividend date of this dividend is Thursday, April 2nd. This represents a $2.52 annualized dividend and a yield of 4.3%. Bristol Myers Squibb’s dividend payout ratio is 73.04%.

Bristol Myers Squibb Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.